{
    "2021-09-01": [
        [
            {
                "time": "2021-08-30",
                "original_text": "上海医药：摩根士丹利、富达国际投资等38家机构于8月30日调研我司",
                "features": {
                    "keywords": [
                        "上海医药",
                        "摩根士丹利",
                        "富达国际投资",
                        "机构调研"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-08-31",
                "original_text": "上海医药(601607)控股股东完成增持H股股份5257万股，占比达1.857%",
                "features": {
                    "keywords": [
                        "上海医药",
                        "上实集团",
                        "增持",
                        "H股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-31",
                "original_text": "上海医药：上实集团累计增持1.857%股份，增持实施完毕",
                "features": {
                    "keywords": [
                        "上海医药",
                        "上实集团",
                        "增持",
                        "股份"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-31",
                "original_text": "上海医药(601607)2021年中报点评：业绩超出预期，创新药管线加速扩张",
                "features": {
                    "keywords": [
                        "上海医药",
                        "中报",
                        "业绩超出预期",
                        "创新药管线"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-31",
                "original_text": "A股头条：中国有色金属工业协会喊话铝价投机者",
                "features": {
                    "keywords": [
                        "中国有色金属工业协会",
                        "铝价",
                        "投机者"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "有色金属"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}